Novel Therapy Elicits Responses in Pancreatic Cancer.
The novel drug SM-88 seems to be a promising therapy for previously treated patients with advanced pancreatic ductal adenocarcinoma. In a phase II trial, the modified dysfunctional tyrosine derivative was well tolerated and elicited responses or led to stable disease in 44% of patients.